Patents by Inventor Thomas P. Cirrito
Thomas P. Cirrito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115677Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, and route of administration for the regimens.Type: ApplicationFiled: April 28, 2023Publication date: April 11, 2024Applicant: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
-
Publication number: 20230374152Abstract: Provided herein are methods for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a peptide derived from the EphA2 protein and/or the IL-13R?2 protein and monitoring the amount of cancer stem cells in the subject. Also provided herein are methods for monitoring the efficacy of an EphA2 peptide-based cancer treatment or an IL-13R?2 peptide-based cancer treatment in a patient with cancer, comprising monitoring the amount of cancer stem cells in the subject prior to, during, and/or following cancer treatment of a patient.Type: ApplicationFiled: August 4, 2022Publication date: November 23, 2023Applicant: Stemline Therapeutics, Inc.Inventors: Thomas P. Cirrito, Ivan Bergstein, Christopher Brooks
-
Publication number: 20230324391Abstract: The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient.Type: ApplicationFiled: November 11, 2022Publication date: October 12, 2023Applicant: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Thomas P. Cirrito
-
Patent number: 11672847Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.Type: GrantFiled: October 10, 2019Date of Patent: June 13, 2023Assignee: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
-
Patent number: 11035863Abstract: Provided herein are improved methods for diagnosing allergy in a subject using designed ankyrin repeat proteins (“DARPins”), and kits for use in such methods. Also provided herein are novel DARPins and methods of use thereof.Type: GrantFiled: January 21, 2016Date of Patent: June 15, 2021Assignee: IMMUNOVENT, LLCInventors: Thomas P. Cirrito, Kate M. Rochlin
-
Publication number: 20210093701Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.Type: ApplicationFiled: October 10, 2019Publication date: April 1, 2021Applicant: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
-
Publication number: 20200330566Abstract: The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective regimens for the prevention, treatment and/or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The therapy(ies) in the prophylactically and/or therapeutically effective regimen can be administered at a lower dose than currently used or known to one of skill in the art and/or for a longer period of time and/or more frequently than currently administered or known to one of skill in the art.Type: ApplicationFiled: November 25, 2019Publication date: October 22, 2020Applicant: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Thomas P. Cirrito
-
Patent number: 10485858Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.Type: GrantFiled: May 15, 2013Date of Patent: November 26, 2019Assignee: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
-
Publication number: 20190175685Abstract: Provided herein are Alanyl-Glutamine (Ala-GIn) formulations for use in treating and preventing side effects associated with cancer treatment. Also provided herein are methods of using the formulations provided herein to treat or prevent side effects associated with cancer treatment.Type: ApplicationFiled: July 31, 2017Publication date: June 13, 2019Inventors: Thomas P. CIRRITO, Kate M. ROCHLIN
-
Publication number: 20190031772Abstract: Provided herein are methods for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a peptide derived from the EphA2 protein and/or the IL-13R?2 protein and monitoring the amount of cancer stem cells in said subject. Also provided herein are methods for monitoring the efficacy of an EphA2 peptide-based cancer treatment or an IL-13R?2 peptide-based cancer treatment in a patient with cancer, comprising monitoring the amount of cancer stem cells in said subject prior to, during, and/or following cancer treatment of a patient.Type: ApplicationFiled: February 12, 2018Publication date: January 31, 2019Inventors: Thomas P. Cirrito, Ivan Bergstein, Christopher Brooks
-
Publication number: 20180364237Abstract: The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient.Type: ApplicationFiled: August 22, 2018Publication date: December 20, 2018Applicant: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Thomas P. Cirrito
-
Publication number: 20180011108Abstract: Provided herein are improved methods for diagnosing allergy in a subject using designed ankyrin repeat proteins (“DARPins”), and kits for use in such methods. Also provided herein are novel DARPins and methods of use thereof.Type: ApplicationFiled: January 21, 2016Publication date: January 11, 2018Applicant: IMMUNOVENT, LLCInventor: Thomas P. Cirrito
-
Publication number: 20170274058Abstract: The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective regimens for the prevention, treatment and/or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The therapy(ies) in the prophylactically and/or therapeutically effective regimen can be administered at a lower dose than currently used or known to one of skill in the art and/or for a longer period of time and/or more frequently than currently administered or known to one of skill in the art.Type: ApplicationFiled: June 12, 2017Publication date: September 28, 2017Inventors: Ivan Bergstein, Thomas P. Cirrito
-
Publication number: 20170146536Abstract: The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient.Type: ApplicationFiled: July 21, 2016Publication date: May 25, 2017Applicant: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Thomas P. Cirrito
-
Publication number: 20150224083Abstract: Provided are methods for treating cancer in a patient, comprising administration of a therapeutically effective regimen of cantharidin or cantharidin analog of formula of formula I, II or III wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, A, Y and Z are as set forth herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. In some embodiments of the methods, the therapeutically effective regimen stabilizes, reduces or eliminates cancer stem cells. In some embodiments of the methods, the therapeutically effective regimen reduces or eliminates cancer cells.Type: ApplicationFiled: October 2, 2014Publication date: August 13, 2015Inventors: Thomas P. Cirrito, Ivan Bergstein
-
Publication number: 20150139939Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.Type: ApplicationFiled: May 15, 2013Publication date: May 21, 2015Applicant: STEMLINE THERAPEUTICS, INC.Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
-
Publication number: 20150079135Abstract: Provided herein are methods for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a peptide derived from the EphA2 protein and/or the IL-13R?2 protein and monitoring the amount of cancer stem cells in said subject. Also provided herein are methods for monitoring the efficacy of an EphA2 peptide-based cancer treatment or an IL-13R?2 peptide-based cancer treatment in a patient with cancer, comprising monitoring the amount of cancer stem cells in said subject prior to, during, and/or following cancer treatment of a patient.Type: ApplicationFiled: March 19, 2013Publication date: March 19, 2015Applicant: STEMLINE THERAPEUTICS, INC.Inventors: Thomas P. Cirrito, Ivan Bergstein, Christopher Brooks
-
Publication number: 20080267947Abstract: Provided are methods for treating cancer in a patient, comprising administration of a therapeutically effective regimen of cantharidin or cantharidin analog of formula of formula I, II or III wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, A, Y and Z are as set forth herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. In some embodiments of the methods, the therapeutically effective regimen stabilizes, reduces or eliminates cancer stem cells. In some embodiments of the methods, the therapeutically effective regimen reduces or eliminates cancer cells.Type: ApplicationFiled: September 7, 2007Publication date: October 30, 2008Inventors: Thomas P. Cirrito, Ivan Bergstein
-
Publication number: 20080118432Abstract: The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and/or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and/or following cancer treatment of a patient.Type: ApplicationFiled: September 7, 2007Publication date: May 22, 2008Inventors: Ivan Bergstein, Thomas P. Cirrito
-
Publication number: 20080118518Abstract: The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective regimens for the prevention, treatment and/or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The therapy(ies) in the prophylactically and/or therapeutically effective regimen can be administered at a lower dose than currently used or known to one of skill in the art and/or for a longer period of time and/or more frequently than currently administered or known to one of skill in the art.Type: ApplicationFiled: September 7, 2007Publication date: May 22, 2008Inventors: Thomas P. Cirrito, Ivan Bergstein